Amgen Inc. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
Amgen Inc. (AMGN) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $154.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Equity › Stockholders' Equity Note
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-05
- Amgen Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-06-30 was $154.00M, a 69.23% increase year-over-year.
- Amgen Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-03-31 was $108.00M, a 31.71% increase year-over-year.
- Amgen Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-12-31 was $10.00M, a 41.18% decline year-over-year.
- Amgen Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-09-30 was $12.00M, a 14.29% decline year-over-year.
- Amgen Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $195.00M, a 23.83% decline from fiscal 2024.
- Amgen Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2024 was $256.00M, a 91.04% increase from fiscal 2023.
- Amgen Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $134.00M, a 3.60% decline from fiscal 2022.
- Amgen Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2022 was $139.00M, a 6.71% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $154.00M 10-Q · filed 2026-08-05 | $262.00M 10-Q · filed 2026-08-05 | $272.00M derived: sum of 3 quarters · filed 2026-08-05 | $284.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $108.00M 10-Q · filed 2026-05-01 | $118.00M derived: sum of 2 quarters · filed 2026-05-01 | $130.00M derived: sum of 3 quarters · filed 2026-05-01 | $221.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $22.00M derived: sum of 2 quarters · filed 2026-02-13 | $113.00M derived: sum of 3 quarters · filed 2026-08-05 | $195.00M 10-K · filed 2026-02-13 |
| 2025-09-30 | $12.00M 10-Q · filed 2025-11-05 | $103.00M derived: sum of 2 quarters · filed 2026-08-05 | $185.00M 10-Q · filed 2025-11-05 | $202.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $91.00M 10-Q · filed 2026-08-05 | $173.00M 10-Q · filed 2026-08-05 | $190.00M derived: sum of 3 quarters · filed 2026-08-05 | $204.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $82.00M 10-Q · filed 2026-05-01 | $99.00M derived: sum of 2 quarters · filed 2026-05-01 | $113.00M derived: sum of 3 quarters · filed 2026-05-01 | $213.00M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $31.00M derived: sum of 2 quarters · filed 2026-02-13 | $131.00M derived: sum of 3 quarters · filed 2026-02-13 | $256.00M 10-K · filed 2026-02-13 |
| 2024-09-30 | $14.00M 10-Q · filed 2025-11-05 | $114.00M derived: sum of 2 quarters · filed 2025-11-05 | $239.00M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $100.00M 10-Q · filed 2025-08-06 | $225.00M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $125.00M 10-Q · filed 2025-05-02 | |||
| 2023-12-31 | $134.00M 10-K · filed 2026-02-13 | |||
| 2023-09-30 | $5.00M 10-Q · filed 2024-10-31 | $74.00M derived: sum of 2 quarters · filed 2024-10-31 | $111.00M derived: sum of 3 quarters · filed 2024-10-31 | |
| 2023-06-30 | $69.00M 10-Q · filed 2024-10-31 | $106.00M derived: sum of 2 quarters · filed 2024-10-31 | ||
| 2023-03-31 | $37.00M 10-Q · filed 2024-10-31 | |||
| 2022-12-31 | $139.00M 10-K · filed 2025-02-14 | |||
| 2022-09-30 | $8.00M 10-Q · filed 2023-10-31 | $77.00M derived: sum of 2 quarters · filed 2023-10-31 | $122.00M derived: sum of 3 quarters · filed 2023-10-31 | |
| 2022-06-30 | $69.00M 10-Q · filed 2023-10-31 | $114.00M derived: sum of 2 quarters · filed 2023-10-31 | ||
| 2022-03-31 | $45.00M 10-Q · filed 2023-10-31 | |||
| 2021-12-31 | $149.00M 10-K · filed 2024-02-14 | |||
| 2021-09-30 | $8.00M 10-Q · filed 2022-11-04 | $84.00M derived: sum of 2 quarters · filed 2022-11-04 | $143.00M derived: sum of 3 quarters · filed 2022-11-04 | |
| 2021-06-30 | $76.00M 10-Q · filed 2022-11-04 | $135.00M derived: sum of 2 quarters · filed 2022-11-04 | ||
| 2021-03-31 | $59.00M 10-Q · filed 2022-11-04 | |||
| 2020-12-31 | $169.00M 10-K · filed 2023-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |